ER+/ HER2-VE Breast Cancer Pipeline Analysis Demonstrates Novel 40+ Therapies at the Horizon Expected to Transform the Treatment Paradigm | DelveInsight
DelveInsight’s, “ER+/ HER2-VE Breast Cancer Pipeline Insight, 2023,” report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in ER+/ HER2-VE Breast Cancer pipeline landscape. It covers the ER+/ HER2-VE Breast Cancer pipeline drug profiles, including ER+/ HER2-VE Breast Cancer clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive ER+/ HER2-VE Breast Cancer pipeline products in this space.
In the ER+/ HER2-VE Breast Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, ER+/ HER2-VE Breast Cancer clinical trials studies, ER+/ HER2-VE Breast Cancer NDA approvals (if any), and product development activities comprising the technology, ER+/ HER2-VE Breast Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the ER+/ HER2-VE Breast Cancer Pipeline Report
- DelveInsight’s ER+/ HER2-VE Breast Cancer Pipeline report depicts a robust space with 40+ active players working to develop 50+ pipeline therapies for ER+/ HER2-VE Breast Cancer treatment.
- The leading ER+/ HER2-VE Breast Cancer Companies includes BeiGene, H3 Biomedicine, AstraZeneca, Olema Pharmaceuticals, CytomX Therapeutics, Roche, G1 Therapeutics, Sanofi, Jiangsu HengRui Medicine, and others.
- Promising ER+/ HER2-VE Breast Cancer Pipeline Therapies includes G1T48, Palbociclib, and others.
- The ER+/ HER2-VE Breast Cancer companies and academics are working to assess challenges and seek opportunities that could influence ER+/ HER2-VE Breast Cancer R&D. The ER+/ HER2-VE Breast Cancer pipeline therapies under development are focused on novel approaches for ER+/ HER2-VE Breast Cancer.
To explore more information on the latest breakthroughs in the ER+/ HER2-VE Breast Cancer Pipeline treatment landscape of the report, click here @ ER+/ HER2-VE Breast Cancer Pipeline Outlook
ER+/ HER2-VE Breast Cancer Overview
HR+ breast cancers are those that express estrogen receptors (ER) or progesterone receptors (PR) or both. These tumors account for 70–80% of all breast cancers. These hormone-dependent cancers can often be treated successfully with a variety of drugs that modulate ER or reduce estrogen. HER2 is short for human epidermal growth factor receptor. HER2 is sometimes called ERBB2, which stands for Erb-B2 receptor tyrosine kinase. HER2 is a gene that produces HER2 proteins, or receptors. If breast cancer cells don’t have abnormal levels of HER2 proteins, the breast cancer is considered HER2-negative.
ER+/ HER2-VE Breast Cancer Emerging Drugs Profile
AZD9833: Astrazeneca
AZD-9833 acts as selective estrogen receptor degraders. It is being developed as combination therapy with palbociclib (a CDK4/6 inhibitor). It is currently in Phase III stage of dvelopement and is being developed by Astrazeneca.
BGB-290: BeiGene
Pamiparib (BGB-290) is an investigational small molecule inhibitor of PARP1 and PARP2. Pamiparib is being evaluated for the treatment of HER2 Negative Breast Cancer. Pamiparib is being evaluated as a monotherapy in pivotal clinical trials in China in recurrent platinum-sensitive and BRCA1/2 mutated ovarian cancers. It is currently in global clinical development as a monotherapy, and in combination with other agents, including BeiGene’s investigational anti-PD1 antibody, tislelizumab (BGB-A317), for a variety of solid tumor malignancies. It is currently in Phase II stage of development for HER2-Negative Breast Cancer and is being developed by Beigene.
For further information, refer to the detailed ER+/ HER2-VE Breast Cancer Unmet Needs, ER+/ HER2-VE Breast Cancer Market Drivers, and ER+/ HER2-VE Breast Cancer Market Barriers, click here for ER+/ HER2-VE Breast Cancer Ongoing Clinical Trial Analysis
ER+/ HER2-VE Breast Cancer Pipeline Therapeutics Assessment
There are approx. 40+ key companies which are developing the ER+/ HER2-VE Breast Cancer. The companies which have their ER+/ HER2-VE Breast Cancer drug candidates in the most advanced stage, i.e. Phase III include, Astrazeneca.
ER+/ HER2-VE Breast Cancer Phases
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Request a sample and discover the recent advances in ER+/ HER2-VE Breast Cancer Ongoing Clinical Trial Analysis and Medications, click here @ ER+/ HER2-VE Breast Cancer Treatment Landscape
Scope of the ER+/ HER2-VE Breast Cancer Pipeline Report
- Coverage- Global
- Companies- BeiGene, H3 Biomedicine, AstraZeneca, Olema Pharmaceuticals, CytomX Therapeutics, Roche, G1 Therapeutics, Sanofi, Jiangsu HengRui Medicine, and others.
- Pipeline Therapies- G1T48, Palbociclib, and others.
- ER+/ HER2-VE Breast Cancer Pipeline Segmentation: Product Type, Molecule Type, Route of Administration, Route of Administration
Dive deep into rich insights for drugs for ER+/ HER2-VE Breast Cancer Market Drivers and ER+/ HER2-VE Breast Cancer Market Barriers, click here @ ER+/ HER2-VE Breast Cancer Unmet Needs and Analyst Views
Table of Content
- Introduction
- Executive Summary
- ER+/ HER2-VE Breast Cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Late Stage Products (Phase III)
- AZD9833: Astrazeneca
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- BGB-290: BeiGene
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- OP-1250: Olema Pharmaceuticals
- Drug profiles in the detailed report…..
- Preclinical Stage Products
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Inactive Products
- ER+/ HER2-VE Breast Cancer Key Companies
- ER+/ HER2-VE Breast Cancer Key Products
- ER+/ HER2-VE Breast Cancer- Unmet Needs
- ER+/ HER2-VE Breast Cancer- Market Drivers and Barriers
- ER+/ HER2-VE Breast Cancer- Future Perspectives and Conclusion
- ER+/ HER2-VE Breast Cancer Analyst Views
- ER+/ HER2-VE Breast Cancer Key Companies
- Appendix
Got Queries? Find out the related information on ER+/ HER2-VE Breast Cancer Mergers and acquisitions, ER+/ HER2-VE Breast Cancer Licensing Activities @ ER+/ HER2-VE Breast Cancer Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
